View
6
Download
0
Category
Preview:
Citation preview
Relapsed Ovarian CancerRelapsed Ovarian CancerH é CURÉ MD PhDHervé CURÉ, MD, PhD
Institut Jean-Godinot, ReimsChampagne-Ardenne University, Reimsp g y,
11th Meeting of the ISGO, Paris-FranceNovember 4-5, 2011
OVCA in elderly patientsOVCA in elderly patients
• Pts 65 years = 48 % in USPts 65 years = 48 % in US• Peak incidence between 75 and 80 years
M d d t (FIGO III C d IV)• More advanced stages (FIGO III C and IV)• Less radical surgery• Bulky residual disease more frequently• Chemotherapy feasibleChemotherapy feasible• Underrepresentation in clinical trials
Hall et al
Cancer. 2003 May 15;97(10
C
Suppl):2701-6.
Click to add text
Hutchins et al.N Engl J Med. 1999 Dec 30;341(27):2061-7.Underrepresentation of patients 65 years of age or older in cancer- treatment trials.
1st L Chemotherapy : is CbP the standard ?1st L Chemotherapy : is CbP the standard ?
•• AGO AGO –– OVAR phase III study OVAR phase III study –– Retrospective subgroup analysisRetrospective subgroup analysis
103 pts (13 %) > 70 years old (Med. 73.5 years)103 pts (13 %) > 70 years old (Med. 73.5 years)
Chemo received / planned dose, tolerance and QoL : NO DIFFERENCE exceptChemo received / planned dose, tolerance and QoL : NO DIFFERENCE except
f b il t i 5 % 1 % ( < 0 001)f b il t i 5 % 1 % ( < 0 001)febrile neutropenia : 5 % vs 1 % (p < 0.001)febrile neutropenia : 5 % vs 1 % (p < 0.001)
early treatment discontinuationearly treatment discontinuation
Hilpert F. et al. Ann Oncol. 2007 Feb;18(2):282Hilpert F. et al. Ann Oncol. 2007 Feb;18(2):282--77p ; ( )p ; ( )
•• COHORT STUDY at the MSKCC COHORT STUDY at the MSKCC
108 pts (37 %) > 65 years old. 108 pts (37 %) > 65 years old. No effect of age on treatment tolerance, PFS and OS No effect of age on treatment tolerance, PFS and OS
Gynecol Oncol 2007 Aug;106(2):381Gynecol Oncol 2007 Aug;106(2):381--77Gynecol Oncol. 2007 Aug;106(2):381Gynecol Oncol. 2007 Aug;106(2):381--77
1st L Chemotherapy : is CbP the standard ?1st L Chemotherapy : is CbP the standard ?
Cb C trial Cb P trial
Pooled analysis of 2 consecutive phase II GINECO studies Pooled analysis of 2 consecutive phase II GINECO studies –– nb= 155 pts nb= 155 pts
Multicentric, specific, few exclusion criteriaMulticentric, specific, few exclusion criteria
Cb C trial Cb P trialMedian age 76 [70 – 90] 75 [70 – 89]PS 0-1 / 2-3 (%) 56 / 44 74 / 26 [p = 0.08]
Optimal surgery (%) 21 41 [p = 0.03]Serous histology (%) 73 71
Stage III / IV (%) 76 / 24 78 / 22Stage III / IV (%) 76 / 24 78 / 22Ascites (%) 59 690 – 3 drugs daily 45 65 [p = 0.03]
FEASIBILITY 72 % vs 68.5 % (NS)
Tredan Freyer et al Annals of
BETTER, BUT…
Tredan, Freyer et al, Annals of Oncology 2007, 18: 256-262
1st L Chemotherapy1st L Chemotherapy : is CbP the standard ?: is CbP the standard ?O ll i l f 2 ti h II GINECO t diO ll i l f 2 ti h II GINECO t diOverall survival of 2 consecutive phase II GINECO studies Overall survival of 2 consecutive phase II GINECO studies
Multivariate analysis :Multivariate analysis :Multivariate analysis :Multivariate analysis :
Paclitaxel use = poor Paclitaxel use = poor prognostic factorprognostic factor
HR = 2.42, p = 0.01HR = 2.42, p = 0.01
Multivariate analysis : poorer Multivariate analysis : poorer survivalsurvival
Stage IV : HR=3,05 Stage IV : HR=3,05 -- p=0.001p=0.0011st L Chemotherapy1st L Chemotherapy : : prognostic factorsprognostic factors g ,g , pp
Paclitaxel : HR=2,42 Paclitaxel : HR=2,42 -- p=0.01p=0.01Depression : HR=5,11 Depression : HR=5,11 -- p
1st L Chemotherapy :1st L Chemotherapy : the GINECO «the GINECO « Elderly Elderly ––CarboplatinCarboplatin » trial (completed end 2009)» trial (completed end 2009)
Med Age 78 years (70 Med Age 78 years (70 –– 93)93)≥ 80 years≥ 80 years 45/11145/111 (40 5%)(40 5%) Etude épigénétique : détermination é è≥ 80 years≥ 80 years 45/111 45/111 (40,5%)(40,5%)PS≥2 PS≥2 48/111 48/111 (43,2%)(43,2%)Depression Depression 20/111 20/111 (18,0%)(18,0%)≥4 drugs / day≥4 drugs / day 76/11176/111 (68,5%)(68,5%)
de la taille des télomères
≥4 drugs / day≥4 drugs / day 76/111 76/111 (68,5%)(68,5%)ADL dependence ADL dependence 61/111 61/111 (55%)(55%)IADL dependence IADL dependence 83/111 83/111 (74,8%)(74,8%)
Measure of telomere length (frailty)
Psychometric / psychological evaluation
Carbo-cyclo trial Carbo-paclitaxel trial
2001 2004 72 pts
Carbo trial
2007 – 2009 – 111 pts1997 – 2000 – 83 pts 2001 – 2004 – 72 pts
p
1st L. Chemotherapy : EWOC i l (i i )EWOC trial (in preparation)
• EWOC = Elderly Women Ovarian CancerEWOC = Elderly Women Ovarian Cancer• International prospective clinical trial
(GINECO + GCIG)(GINECO + GCIG)• Randomized phase II
– Arm A = Carbo AUC 5 + Pacli 135 mg/sqm– Arm B = Carbo AUC 5– Arm C = weekly Carbo AUC 2 + Pacli 60 mg/sqm
(MITO protocol)
RELAPSE in OVCA : id i lepidemiology
• 75 % of recurrence after 1st L. CT (10 % per % ( % pyear in pCR)
• Median TTP after 1st L. CT = 16 to 22 months• Median time of survival after recurrence of 2
yearsP ti f t f l• Prognostic factors of relapse :– pCR after 1st L.CT– Histological typeHistological type
• Prognostic factor after relapse = length of free interval without CT
RELAPSE in OVCA
• Retrospective study of GINECO h II/III
1,0> 18
TFI in months
GINECO phase II/III studies (nb =583 pts)
viva
l
,8
,6
12-18
3-12
p= . 0001
• Objective : – Impact of free interval o
vera
ll su
rv,4
0-3
0-3non-progressive
on overall survival
10008006004002000
,2
0,0
progressive
E.Pujade-Lauraine - Proc. ASCO 2002
days
RELAPSE in OVCA :Guidelines of the NICE
( f C )
RELAPSE in OVCA :Guidelines of the NICE
( f C )(National Institute for Clinical Excellence)(National Institute for Clinical Excellence)
1st L Paclitaxel-Carboplatin1st L Paclitaxel-Carboplatin
55% 25%20%
SensibleSensible Partially sensiblePartially sensible
Resistant/RefractoryResistant/Refractory
55% 25%20%
(> 12 months)(> 12 months)sensible
(6-12 months)sensible
(6-12 months)Refractory
(< 6 monthsRefractory
(< 6 months
Paclitaxel-CarboplatinCaelyx-Carboplatin
Paclitaxel-CarboplatinCaelyx-Carboplatin
Paclitaxel-CarboplatinCAELYX® mono
Yondelis Caelyx
Paclitaxel-CarboplatinCAELYX® mono
Yondelis Caelyx
Paclitaxel mono(weekly +++)CAELYX® mono
Topotecan
Paclitaxel mono(weekly +++)CAELYX® mono
Topotecan
NHS. Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. Guidance 28, 45 and 55. Mai 2005
y py p Yondelis-CaelyxYondelis-Caelyx TopotecanTopotecan
P l t d li l d bi i dPegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin
in platinum sensitive ovarian cancerin platinum-sensitive ovarian cancer patients:
Treatment at recurrence and overall survival final analysis from CALYPSO phase IIIfinal analysis from CALYPSO phase III
GCIG trial
Marth et al. J Clin Oncol 2011;29 (suppl; abstr 5052)
Background
CALYPSO is a large international randomized phase III trial comparing C-PLD and C-P in pts with OC in late relapse.
• From 04/05 to 09/07, 976 eligible pts were randomized to either C-P(carboplatin AUC 5 iv d1 + paclitaxel [P] 175 mg/m2 3h iv d1, q3w) orC-PLD (Carboplatin + PLD 30 mg/m2 iv d1 q4w) for at least 6 cycles.
• Results of the progression-free survival (PFS), the primary endpoint,show a benefit in pts treated with C-PLD with a hazard ratio (HR) of 0.82 (P =.005)1.
• Overall severe non-hematologic toxicity (36 8% v 28 4%; P < 01)Overall severe non-hematologic toxicity (36.8% v 28.4%; P < .01) including alopecia, neurotoxicity and carboplatin hypersensitivity leading to early discontinuation (15% v 6%; P < .001) –occurred more frequently in the C-P arm
• It was explored whether the treatment effect on PFS recently observed in CALYPSO was maintained after further treatment. OS of pts was analysed.
Patients were followed for 49 months (range 0-68 mo)Patients were followed for 49 months (range 0 68 mo)
1 : E. Pujade-Lauraine et al., J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24.
CALYPSO: Study designCALYPSO: Study designInternational, Intergroup, Open-label, Randomized Phase III Study
Ovarian cancer in late relapse (> 6 months) after 1st- or 2nd-line
RA
Experimental arm: CDPLD 30 mg/m2 IV d 1after 1 or 2 line
platinum-based therapy (previous taxane
required)
NDOM
PLD 30 mg/m IV d 1Carboplatin AUC 5 d 1
Q 28 days x 6 courses*q )
Stratification:•Therapy-free interval (6-12 mo vs > 12 mo)
MIZE
Control arm: CPPaclitaxel 175 mg/m2 IV d 1Carboplatin AUC 5 d 1( )
•Measurable disease (yes vs no)•Center
E Carboplatin AUC 5 d 1Q 21 days x 6 courses*
*or progression in patients with SD or PRor progression in patients with SD or PR
Pujade-Lauraine E et al. J Clin Oncol 2010; 28(30): 3323-3329
Overall Survival
1.0
0.8
Median OS30.7 (C-PLD) vs 33.0 (C-P) monthsHR 0.994, (95% CI 0.85-1.16); p=0.937
0.6
0.4
C-P
C-PLD
opor
tion
Aliv
e
0.2
0.00 6 12 18 24 30 36 42 48 54
logRank = 0.937
Pro
0 6 12 18 24 30 36 42 48 54Months from randomisationNumber at risk
466509
408446
285327
194213
9177
C-PLDC-P
C-PLD C-P
663 Deceased ( 312 censored) 317 (149) 346 (163)
Median Overall Survival (months) (HR 0.994 (95% CI: 0.85-1-16); p=0.937 30.7 33.0
Therapy fee interval (6-12 m vs > 12m) (p1 (p
Number of treatment lines post CalypsoNumber of treatment lines given after Calypso
0 li5 11 li
Number of treatment lines post Calypso
10%
21%
13%10%
0 line
1 line4 lines
5-11 lines
21%
21% 2 lines
3 lines
25%
Most patients (70%) received 2 or more lines of chemotherapy after Calypso treatment
Cross Over Post Calypso
20%
16%
18%
20%
10%
12%
14%
ss-o
ver
Arm CaC
4%
6%
8%Cro
s Arm CaCArm TC
0%
2%
1 2 3 4 5 6 7 8
N b f li ft C lThe number of patients who received PLD in C-P arm (68%) was significantly higher (p
Elderly patients in CALYPSO studyElderly patients in CALYPSO study
• 157 pts (= 16 %) > 70 years old157 pts ( 16 %) 70 years old• Median age = 73 years old (70-82 y)• PS
CONCLUSIONSCONCLUSIONS• OVCA is a chemosensitive but not a
chemocurative disease• Effectiveness of relapse treatments but not
lastinglasting• Dramatic underrepresentation of elderly patients
in clinical trials
Urgence to enrolle 5 % and more of patients 75 years old in specific clinical trials conformed to INCay precommandation (National Institute of Cancer, France) with the support of SoFOG (French Society of Geriatric Oncology)gy)
Recommended